Samsung Bioepis' Opuviz Receives European Approval, Accelerating Entry into the Eylea Biosimilar Market
Transition to an Independent European Direct Sales System and Commercialization
The European Commission (EC) has officially approved Opuviz, Samsung Bioepis' biosimilar to Eylea, marking a significant milestone in expanding treatment access for European patients suffering from retinal diseases such as neovascular Age-related Macular Degeneration (nAMD). Samsung Bioepis has made a bold decision to terminate its partnership with Biogen and transition to a direct commercialization system for ophthalmic biosimilars in Europe, fully recovering the rights. This move is analyzed as a strategic step to maximize profitability in the European market by reducing distribution costs and flexibly responding to market changes.
Mechanism of Action and Clinical Equivalence through Inhibition of Blood Vessel Formation
Opuviz works by binding to Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PlGF), inhibiting the formation of abnormal new blood vessels. In a Phase 3 clinical trial, Opuviz demonstrated high clinical equivalence to the original drug, Eylea, in terms of changes in Best-Corrected Visual Acuity (BCVA) in patients with nAMD. Furthermore, clinical data from a study in which patients were switched from the original drug to Opuviz at week 32 showed no significant differences in efficacy, safety, or immunogenicity. Based on this robust clinical data, Opuviz is expected to gain high prescription confidence among European physicians.
Intensified Multinational Competition in the Eylea Market
The European anti-VEGF market is a massive scale, with the original drug, Eylea, generating annual global sales of $9.5 billion in 2024, with sales outside the United States reaching $3.6 billion. With the approval of Opuviz, fierce competition for market share is inevitable with other approved products such as Afqlir from Sandoz and Yesafili from Biocon. The original manufacturers, Regeneron and Bayer, are also launching a defense with a high-dose formulation (Eylea HD), making price competitiveness among biosimilars even more important. Accordingly, Samsung Bioepis plans to employ a marketing strategy that leverages its direct sales flexibility to gain an advantage in price competition.
Challenges in Securing National Insurance Coverage and Early Market Penetration
In the European market, negotiations with national health authorities regarding pricing and reimbursement, as well as securing coverage under national health insurance, will be key to future commercial success. As biosimilar preferential policies and tender systems vary by country, a sophisticated customized entry strategy is essential. Opuviz has already obtained approval from the U.S. Food and Drug Administration (FDA) in May 2024 and has now completed approval in the European market, completely resolving global regulatory risks. The extent to which Samsung Bioepis' mid- to long-term healthcare revenue contribution will increase will depend on the success of its direct sales organization and the results of price negotiations in each country.
In the global $9.5 billion Eylea market, Opuviz's European approval will be a turning point for Samsung Bioepis to fully demonstrate its independent commercial capabilities. In the short term, it will be necessary to increase sales and marketing expenses due to the termination of existing partnerships in Europe and the establishment of a direct sales network. However, in the medium to long term, it will gain strategic advantages such as maximizing profitability by reducing distribution costs and securing an independent European distribution platform. If Opuviz can achieve early market penetration based on the equivalence and switching data proven in Phase 3 clinical trials, it will be able to rapidly erode the market share in the $3.6 billion Eylea market outside the United States and play a solid role as a cash cow. In order to counter the simultaneous entry of competing biosimilars such as Sandoz's Afqlir and Biocon's Yesafili, and the high-dose defense strategy of the original manufacturer, it is expected that the flexibility of price policy in national tender markets will be a key indicator of future commercial success.
Source: EMA (ema)